ArticleScientific reports2025
Impaired antibody responses to heterologous ChAdOx1 nCoV-19 and BNT162b2 vaccination in individuals with type 2 diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The COVID-19 pandemic has caused many deaths worldwide, especially in patients with type 2 diabetes mellitus (DM). Owing to the association of type 2 DM with immune dysfunction, we evaluated the impact of DM on the humoral immune responses induced by inactivated (Sinovac, SV), viral vector (ChAdOx1 nCoV-19, Az) and mRNA (BNT162b2, BNT) vaccines, compared with those in non-DM individuals. The levels of anti-spike (S) and neutralizing antibodies (nAbs) against the S1 domain/receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) before and after COVID-19 vaccination were determined. The immune response in non-DM individuals heterologously immunized with the Az-BNT regimen was more robust than that in those immunized with other regimens. Notably, individuals with type 2 DM presented reduced anti-S antibody levels following vaccination with the Az-BNT regimen at 30 and 90 days post-vaccination. Furthermore, a rapid decline in nAb levels in DM individuals was noted on day 90 post-boost for all regimens. Thus, a shorter interval between boosters might be necessary for DM individuals. These findings could inform the selection of optimal vaccination protocols for individuals with or without DM and contribute to the development of an efficacious COVID-19 vaccine for individuals with underlying health conditions, particularly DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.